Flu Vaccine Cut Risk for Influenza-Linked Hospitalizations in 2023
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 11, 2023 -- Influenza vaccination reduced the risk for influenza-associated hospitalizations by 52 percent in the March to September Southern Hemisphere 2023 influenza season, according to research published in the Sept. 8 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Ashley L. Fowlkes, Sc.D., from the CDC in Atlanta, and colleagues conducted an interim study to estimate vaccine effectiveness (VE) for preventing severe acute respiratory infection (SARI)-associated hospitalization using data from the Network for the Evaluation of Vaccine Effectiveness in Latin America and the Caribbean-influenza (la Red para la Evaluación de Vacunas en Latino América y el Caribe-influenza [REVELAC-i]).
The researchers found that the adjusted VE against SARI hospitalization associated with any influenza virus during the 2023 Southern Hemisphere season was 51.9 percent, including 55.2 percent against the predominating A(H1N1)pdm09, based on data contributed by Argentina, Brazil, Chile, Paraguay, and Uruguay on 2,780 SARI patients hospitalized during March 27 to July 9, 2023.
"Preliminary REVELAC-i data from five Southern Hemisphere countries suggest that influenza vaccines were effective in preventing more than one half of influenza-associated hospitalizations among young children, persons with preexisting conditions, and older adults," the authors write. "Evaluating influenza VE through integrated regional networks such as REVELAC-i provides valuable information that can guide public health practice."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
COVID-19 Vaccination Not Tied to Adverse Pregnancy Outcomes
TUESDAY, June 25, 2024 -- mRNA COVID-19 vaccination during pregnancy is not associated with an increased risk of adverse pregnancy outcomes, according to a study published in the...
FDA Approves Capvaxive Pneumococcal 21-Valent Conjugate Vaccine
FRIDAY, June 21, 2024 -- The U.S. Food and Drug Administration has approved the Capvaxive pneumococcal 21-valent conjugate vaccine for the prevention of invasive pneumococcal...
No Evidence That Live Vaccines Are Unsafe for Patients on Dupilumab
FRIDAY, June 14, 2024 -- There is no evidence to suggest that administration of live vaccines to patients receiving dupilumab is unsafe, and vaccine efficacy is not affected by...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.